




Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: AMRN	
Last Trade:	2.98
Trade Time:	4:00 PM ET May 26, 2017
Change:	-0.07  (-2.295%)
Day Range	2.96 - 3.08
52-Week Range	1.87 - 3.65
Volume	779,633

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.


Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 18, 2017*
[Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care](#)
- May 3, 2017*
[Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations](#)
- Apr 25, 2017*
[Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017](#)
- Mar 21, 2017*
[Amarin Corporation CEO, John Thero, to Chair the American Heart Association's Heart & Stroke Ball in New York City](#)
- Mar 16, 2017*
[Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*
[Quarterly Report \(10-Q\)](#)